
Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
9/4/2026
0:00
8:31
Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease.
Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health
More episodes from "NeuroFrontiers"



Don't miss an episode of “NeuroFrontiers” and subscribe to it in the GetPodcast app.








